In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Aslan Pharmaceuticals (ASLN - Research Report), with a price target of $7.00. The company's shares closed yesterday at $0.78.According to TipRanks, Chen is an analyst with an average return of -14.6% and a 30.62% success rate. Chen covers the Healthcare sector, focusing on stocks such as Veru, Applied DNA Sciences, and Aslan Pharmaceuticals.Aslan Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $7.00.See the top stocks recommended by analysts >>The company has a one-year high of $3.36 and a one-year low of $0.36.
https://www.tipranks.com/news/blurbs/h-c-wainwright-remains-a-buy-on-aslan-pharmaceuticals-asln?utm_source=advfn.com&utm_medium=referral
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more ASLAN Pharmaceuticals Charts.
ASLAN Pharmaceuticals (NASDAQ:ASLN)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more ASLAN Pharmaceuticals Charts.